Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali Volume 6 Issue 2 (2025)

EARLY MOLECULAR AND IMMUNE MARKERS AS A BASIS FOR DIFFERENTIATED THERAPY OF TYPE 2 AUTOIMMUNE POLYGLANDULAR SYNDROME (LITERATURE REVIEW)

Арипова Тамара Уктамовна, Негматова Гулзода Шухратовна, Халимова Замира Юсуповна

Read at source PDF

Abstract

Type 2 autoimmune polyglandular syndrome (APS-2) is a complex endocrine disorder characterized by a combination of autoimmune pathologies, such as Addison’s disease, autoimmune thyroiditis, and type 1 diabetes mellitus. Despite significant progress in the study of APS-2, its pathogenesis, diagnosis, and therapy remain relevant research areas. This literature review examines modern molecular and immune markers that play a key role in the early detection and prognosis of the disease. Genetic predispositions, including HLA-DR3 and HLA-DR4 alleles, as well as polymorphisms in the CTLA-4, PTPN22, FOXP3, and STAT4 genes, are analyzed. Special attention is paid to epigenetic factors such as DNA methylation and the influence of non-coding RNAs on immune mechanisms. Key immune markers, including autoantibodies to 21-hydroxylase, GAD65, and IA-2, as well as the role of pro-inflammatory cytokines and changes in the T-lymphocyte population, are considered. The review highlights prospects for differentiated therapy, including targeted monoclonal antibodies, antigen-specific immunotherapy, cellular technologies, and metabolic regulation. Further research into APS-2 mechanisms will contribute to the improvement of diagnostic and therapeutic approaches, enhancing the effectiveness of personalized medicine in endocrinology.

аутоиммунный полигландулярный синдром 2 типа, аутоантитела, таргетная терапия, иммуномодуляция, персонализированная медицинаtype 2 autoimmune polyglandular syndrome, autoantibodies, targeted therapy, immunomodulation, personalized medicine2-tur avtoimmun poliglandulyar sindrom, avtoantitanalar, nishonga yo‘naltirilgan terapiya, immunomodulyatsiya, shaxsga yo‘naltirilgan tibbiyot

Metadata source: the journal's OAI-PMH archive · Sindex does not store the full text; it links to the source.

Cite

APA 7 
Арипова Тамара Уктамовна, Негматова Гулзода Шухратовна & Халимова Замира Юсуповна (2025). EARLY MOLECULAR AND IMMUNE MARKERS AS A BASIS FOR DIFFERENTIATED THERAPY OF TYPE 2 AUTOIMMUNE POLYGLANDULAR SYNDROME (LITERATURE REVIEW). Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali, 6(2).
GOST R 7.0.5 
Арипова Тамара Уктамовна, Негматова Гулзода Шухратовна, Халимова Замира Юсуповна EARLY MOLECULAR AND IMMUNE MARKERS AS A BASIS FOR DIFFERENTIATED THERAPY OF TYPE 2 AUTOIMMUNE POLYGLANDULAR SYNDROME (LITERATURE REVIEW) // Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali. 2025. Т. 6. № 2.
BibTeX 
@article{уктамовна2025,
  author  = {Арипова Тамара Уктамовна and Негматова Гулзода Шухратовна and Халимова Замира Юсуповна},
  title   = {EARLY MOLECULAR AND IMMUNE MARKERS AS A BASIS FOR DIFFERENTIATED THERAPY OF TYPE 2 AUTOIMMUNE POLYGLANDULAR SYNDROME (LITERATURE REVIEW)},
  journal = {Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali},
  year    = {2025},
  volume  = {6},
  number  = {2}
}
RIS 
TY  - JOUR
AU  - Арипова Тамара Уктамовна
AU  - Негматова Гулзода Шухратовна
AU  - Халимова Замира Юсуповна
TI  - EARLY MOLECULAR AND IMMUNE MARKERS AS A BASIS FOR DIFFERENTIATED THERAPY OF TYPE 2 AUTOIMMUNE POLYGLANDULAR SYNDROME (LITERATURE REVIEW)
JO  - Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali
PY  - 2025
VL  - 6
IS  - 2
ER  -